Trials in Kansas City, Missouri
Here are the top 10 medical studies for lung cancer in Kansas City, Missouri
Popular Filters
Phase 3 Trials
Chemotherapy
Adagrasib + Pembrolizumab for Lung Cancer
Recruiting1 awardPhase 2 & 3
Wichita, Kansas
This trial tests two drugs, MRTX849 and pembrolizumab, in patients with advanced lung cancer who have a specific genetic mutation. MRTX849 targets the mutation to stop cancer growth, while pembrolizumab boosts the immune system to fight the cancer. The study aims to see how well these treatments work alone and together.
Tyrosine Kinase Inhibitor
Crizotinib for Non-Small Cell Lung Cancer
Recruiting2 awardsPhase 3
Fort Smith, Arkansas
This trial studies crizotinib for patients with stage IB-IIIA NSCLC who have had surgery and have an ALK fusion mutation. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working.
Anti-tumor antibiotic
ONC-392 vs Chemotherapy for Lung Cancer
Recruiting2 awardsPhase 3
Wichita, Kansas
This trial is testing gotistobart, a new drug that helps the immune system fight advanced lung cancer in patients who haven't responded to other treatments. It works by blocking a protein that allows cancer cells to hide from the immune system.
Trials With No Placebo
Monoclonal Antibodies
Patritumab Deruxtecan for Non-Small Cell Lung Cancer
Recruiting1 awardPhase 2
Kansas City, Kansas
This trial is testing a new drug called patritumab deruxtecan for patients with advanced lung cancer who have specific genetic mutations and have not responded to other treatments. The drug targets cancer cells specifically and delivers chemotherapy directly to them.
Chemotherapy
Adagrasib + Pembrolizumab for Lung Cancer
Recruiting1 awardPhase 2 & 3
Wichita, Kansas
This trial tests two drugs, MRTX849 and pembrolizumab, in patients with advanced lung cancer who have a specific genetic mutation. MRTX849 targets the mutation to stop cancer growth, while pembrolizumab boosts the immune system to fight the cancer. The study aims to see how well these treatments work alone and together.
Tyrosine Kinase Inhibitor
Selpercatinib for Non-Small Cell Lung Cancer
Recruiting1 awardPhase 2
Carthage, Illinois
This trial will study how well selpercatinib works in treating patients with RET fusion-positive non-small cell lung cancer. Selpercatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
View More Related Trials
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.